Sialidosis is characterized by a deficiency of the digestive enzyme, alpha-neuraminidase. The lack of this enzyme results in an abnormal accumulation of complex carbohydrates known as mucopolysaccharides, and of fatty substances known as mucolipids. Both of these substances accumulate in bodily tissues. There are four types of Sialidosis: Each type of Sialidosis is characterized by the age of onset and by the type of physical and mental manifestations of this disorder.
DelveInsight’s “Sialidosis Market Insights, Epidemiology, and Market Forecast-2032″ report delivers an in-depth understanding of the Sialidosis, historical and forecasted epidemiology as well as the Sialidosis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Some facts of Sialidosis Market are:
- As per the International Advocate for Glycoprotein Storage Diseases (ISMRD), Type I is the mildest form of Sialidosis, with a range of onset from anywhere between 8-25 years of age. Type II Sialidosis has an earlier age of onset and more severe symptoms than type I. The congenital form of type II Sialidosis has an onset before birth and symptoms will be present in the new born period.
- As per ISMRD, Sialidosis is among the rarest Lysosomal Storage Diseases, affecting perhaps less than 1:4,000,000 worldwide and is thought to be more common in people with Italian ancestry.
- According to NORD, Sialidosis affects males and females in equal number.
- As per National Center for Advanced Translational Sciences, Sialidosis type II is the more severe type of the disorder than type I and often begins during infancy or later during childhood.
Request for Free Sample Report: https://www.delveinsight.com/sample-request/sialidosis-market
Key Highlights of the Sialidosis Market Report
- The report covers the descriptive overview of Sialidosis, explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies
- Comprehensive insight has been provided into the Sialidosis epidemiology and treatment in the 7MM
- Additionally, an all-inclusive account of both the current and emerging therapies for Sialidosis is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
- A detailed review of the Sialidosis market; historical and forecasted is included in the report, covering drug outreach in the 7MM
- The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Sialidosis market.
Sialidosis is an autosomal recessive lysosomal storage disease caused by pathogenic variants in NEU1 which encodes lysosomal sialidase (neuraminidase 1). Lysosomal neuraminidase catalyzes the removal of terminal sialic acid molecules from glycolipids, glycoproteins, and oligosaccharides.
Type I is the mildest form of Sialidosis, with a range of onset from anywhere between 8-25 years of age. Many of the characteristic features of lysosomal storage diseases including coarse facial features, hepatosplenomegaly (large liver and/or spleen), and dysostosis multiplex (abnormal bone formation that is found in multiple bones of the body) are absent.
Type II Sialidosis has an earlier age of onset and more severe symptoms than type I. The congenital form of type II Sialidosis has an onset before birth and symptoms will be present in the newborn period. Often, these babies have hydrops (accumulation of fluid in the body) and do not survive the newborn period. Individuals that survive typically have mental retardation and severe epatosplenomegaly. Facial features are coarse and dysostosis multiplex is present.
Major Sialidosis Market Players:-
- Novartis AG,
- Pfizer Inc.,
- Johnson & Johnson Private Limited,
- Abbott,
- GlaxoSmithKline plc,
- UCB S.A.,
- Teva Pharmaceutical Industries Ltd., and Takeda Pharmaceutical Company Limited
- And Others
Scope of the Report:
- Study Period: 2019-2032
- Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
- Key Critical Limb Ischemia Companies: Novartis AG, Pfizer Inc., Johnson & Johnson Private Limited, Abbott, GlaxoSmithKline plc, UCB S.A., Teva Pharmaceutical Industries Ltd., and Takeda Pharmaceutical Company Limited, And Others
- Therapeutic Assessment: Sialidosis current marketed and emerging therapies
- Sialidosis Market Dynamics: Sialidosis market drivers and barriers
- Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
- Unmet Needs, KOL’s views, Analyst’s views, Sialidosis Market Access and Reimbursement
Request for Free Sample Report: https://www.delveinsight.com/sample-request/sialidosis-market
Table of Content:
1. Key Insights
2. Executive Summary of Sialidosis
3. Competitive Intelligence Analysis for Sialidosis
4. Sialidosis: Market Overview at a Glance
5. Sialidosis: Disease Background and Overview
6. Patient Journey
7. Sialidosis Epidemiology and Patient Population
8. Treatment Algorithm, Current Treatment, and Medical Practices
9. Sialidosis Unmet Needs
10. Key Endpoints of Sialidosis Treatment
11. Sialidosis Marketed Products
List to be continued in report
12. Sialidosis Emerging Therapies
List to be continued in report
13. Sialidosis: Seven Major Market Analysis
14. Attribute analysis
15. 7MM: Market Outlook
16. Access and Reimbursement Overview of Sialidosis
17. KOL Views
18. Market Drivers
19. Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +19193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/report-store/sialidosis-market?utm_source=SatPR&utm_medium=pressrelease&utm_campaign=apr